Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03125824 · ClinicalTrials.gov registry record · NA

Soliton Planar Acoustic Wave Device System for Dermal Tattoo Clearing Human Trial Protocol

A NA study of Tattooing, sponsored by Soliton.

Completed
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT03125824: Completed NA study of Tattooing, sponsored by Soliton.

NCT03125824 is a NA study of Tattooing that has completed, run by Soliton. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03125824, a NA study of Tattooing, has completed, sponsored by Soliton.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

To further evaluate accelerated fading resulting from additional treatment sessions of Soliton AWD as accessory to laser in tattoo reduction treatment.

Primary Outcome

To evaluate changes in accelerated fading of previously treated tattoos from original treatment with additional treatment sessions of Soliton Acoustic Wave Device as an accessory to laser treatment through comparison of photographic evidence. Changes are measured by comparing photos of the tattoos after the original treatment to photos of the tattoos after additional treatment.

Conditions Studied

Interventions

  • DEVICE Soliton Acoustic Wave Device

Study Locations (1)

Massachusetts

  • SkinCare Physicians - Chestnut Hill

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2017-02-13
Est. Completion 2018-09-25
Phase NA
Soliton

7 total trials

What the finished NCT03125824 record still lists

NCT03125824 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Tattooing appearing as the primary indexed condition, and to 1 intervention - of which Soliton Acoustic Wave Device is the first listed.

NCT03125824 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03125824 about?

NCT03125824 is a clinical study titled "Soliton Planar Acoustic Wave Device System for Dermal Tattoo Clearing Human Trial Protocol". To further evaluate accelerated fading resulting from additional treatment sessions of Soliton AWD as accessory to laser in tattoo reduction treatment.

What is the current status of trial NCT03125824?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2017-02-13. Estimated completion is 2018-09-25.

What conditions does trial NCT03125824 study?

This clinical trial studies the following conditions: Tattooing.

What interventions are being tested in trial NCT03125824?

The interventions under investigation include: Soliton Acoustic Wave Device (DEVICE).

Who is sponsoring clinical trial NCT03125824?

This trial is sponsored by Soliton, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03125824 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT03125824's enrollment target sits among peer trials

20 1768th of 2000 higher than 140 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03125824, the US trial registry maintained by the National Library of Medicine. NCT03125824 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.